A Small Molecule p75NTR Ligand, LM11A-31, Reverses Cholinergic Neurite Dystrophy in Alzheimer's Disease Mouse Models with Mid- to Late-Stage Disease Progression by Simmons, Danielle A. et al.
A Small Molecule p75NTR Ligand, LM11A-31, Reverses
Cholinergic Neurite Dystrophy in Alzheimer’s Disease
Mouse Models with Mid- to Late-Stage Disease
Progression
Danielle A. Simmons1, Juliet K. Knowles1,2, Nadia P. Belichenko1, Gargi Banerjee1, Carly Finkle1,
Stephen M. Massa3, Frank M. Longo1,2*
1 Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, United States of America, 2 Department of Neurology, University of North
Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 3 Department of Neurology and Laboratory for Computational Neurochemistry and Drug
Discovery, San Francisco Veterans Affairs Medical Center, and Department of Neurology, University of California San Francisco, San Francisco, California, United States of
America
Abstract
Degeneration of basal forebrain cholinergic neurons contributes significantly to the cognitive deficits associated with
Alzheimer’s disease (AD) and has been attributed to aberrant signaling through the neurotrophin receptor p75 (p75NTR).
Thus, modulating p75NTR signaling is considered a promising therapeutic strategy for AD. Accordingly, our laboratory has
developed small molecule p75NTR ligands that increase survival signaling and inhibit amyloid-b-induced degenerative
signaling in in vitro studies. Previous work found that a lead p75NTR ligand, LM11A-31, prevents degeneration of cholinergic
neurites when given to an AD mouse model in the early stages of disease pathology. To extend its potential clinical
applications, we sought to determine whether LM11A-31 could reverse cholinergic neurite atrophy when treatment begins
in AD mouse models having mid- to late stages of pathology. Reversing pathology may have particular clinical relevance as
most AD studies involve patients that are at an advanced pathological stage. In this study, LM11A-31 (50 or 75 mg/kg) was
administered orally to two AD mouse models, Thy-1 hAPPLond/Swe (APPL/S) and Tg2576, at age ranges during which marked
AD-like pathology manifests. In mid-stage male APPL/S mice, LM11A-31 administered for 3 months starting at 6–8 months of
age prevented and/or reversed atrophy of basal forebrain cholinergic neurites and cortical dystrophic neurites. Importantly,
a 1 month LM11A-31 treatment given to male APPL/S mice (12–13 months old) with late-stage pathology reversed the
degeneration of cholinergic neurites in basal forebrain, ameliorated cortical dystrophic neurites, and normalized increased
basal forebrain levels of p75NTR. Similar results were seen in female Tg2576 mice. These findings suggest that LM11A-31 can
reduce and/or reverse fundamental AD pathologies in late-stage AD mice. Thus, targeting p75NTR is a promising approach
to reducing AD-related degenerative processes that have progressed beyond early stages.
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Introduction
Degeneration of basal forebrain cholinergic neurons (BFCN)
and their neurites is a major contributing factor to the cognitive
dysfunction associated with Alzheimer’s disease (AD). It precedes
neuron loss and is associated with mild cognitive impairment, a
predecessor of AD [1]. BFCN atrophy involves aberrant signaling
through the neurotrophin receptor p75 (p75NTR). p75NTR is
abundantly expressed by these neurons in adulthood [2] and its
signaling can positively or negatively affect the condition of
BFCNs depending on the presence of several factors including co-
receptors and ligands [3,4]. For example, nerve growth factor
(NGF) signaling through p75NTR may promote cell survival or
death depending on the presence of its high-affinity receptor TrkA
[3,4]. Neuronal degeneration also occurs when amyloid-b (Ab)1–40
binds to p75NTR [5,6]. Moreover, BFCNs were found to
degenerate when Ab oligomers were delivered to the brains of
wild-type (WT) but not p75NTR deficient mice [7], and this
degeneration was prevented by functionally removing the neuro-
trophin-binding domain of the receptor in an AD mouse model
[8]. Together, these observations indicate that p75NTR signaling
plays a necessary role in enabling Ab-induced degeneration and
implicate it as an AD therapeutic target [9,10,11].
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Accordingly, our laboratories have developed small molecule,
non-peptide ligands of p75NTR that promote survival-related
signaling, inhibit Ab-induced degenerative signaling, and reduce
degeneration in Ab-exposed neuronal cultures [10,12,13]. One
such ligand, LM11A-31, is a water soluble amino acid derivative
that reaches the CNS [14,15] and has structural and chemical
features similar to the NGF loop 1 domain, which is known to
interact with p75NTR [12]. LM11A-31 prevents BFCN atrophy
and cognitive deficits in an AD mouse model when administration
starts at early pathological stages of the disease, shortly after Ab
plaques appear [14,16]. A frequent occurrence in AD drug
development is that compounds eliciting promising results in
preclinical models fail to produce positive outcomes in clinical
trials. One potential reason for this failing is that, in most
preclinical studies, therapy is initiated in animals exhibiting little or
no pathology or behavioral symptoms, while clinical studies of AD
therapies involve symptomatic patients at more advanced patho-
logical stages [17,18]. Until it is possible to reliably identify early
stages of AD pathology in the clinical setting, a key strategy for
preclinical testing of potential therapeutics will be to apply them to
symptomatic animals with moderate to severe neuropathology
which better corresponds to the clinical population. Therefore, this
study examined whether LM11A-31 could arrest or reverse the
degeneration of cholinergic neurites in two well characterized AD
models, Thy-1 hAPPLond/Swe (APPL/S) and Tg2576 mice, with
treatment beginning in mid- to late stages of disease progression
characterized by the presence of abundant amyloid deposits, well
established BFCN degeneration, and memory deficits apparent in
multiple testing paradigms [14,16,19,20,21].
Materials and Methods
Ethics statement
All animal procedures were conducted in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals. Studies were performed at Stanford Univer-
sity with protocols approved by its Institutional Animal Care and
Use Committee and at the Palo Alto Veteran’s Administration
Hospital with approval of its Committee on Animal Research.
Protocols included efforts to minimize animal suffering and
numbers of mice used.
AD mouse models
Two mouse lines were used in these studies: 1) Thy-1 hAPP
transgenic line 41 C57BL/6 which over-express human amyloid
precursor protein (APP) 751 (hAPP751) containing the London
(V717I) and Swedish (K670M/N671L) mutations under the
murine Thy1 promoter [19], which will herein be referred to as
APPL/S; and 2) Tg2576, which over-express the 695 amino acid
human isoform of APP with the ‘‘Swedish’’ mutation [22].
p75NTR ligand
LM11A-31 [2-amino-3-methyl-pentanoic acid (2-morpholin-4-
yl-ethyl)-amide] is a water soluble isoleucine derivative (MW
243.3); for structure and detailed pharmacological characteriza-
tion see Massa et al. (2006) and Knowles et al. (2013). LM11A-31
was custom manufactured by Ricerca Biosciences (Painesville,
OH) at .97% purity, as assessed by liquid chromatography/mass
spectroscopy (LC-MS/MS) analysis.
LM11A-31 treatment
Both lines of transgenic mice and their gender- and age-
matched non-transgenic (WT) littermates were randomly assigned
to either vehicle or LM11A-31 treatment groups. For male APPL/S
mice, treatment started at two different ages: 1) 6–8 month old
mice were treated for 3 months prior to euthanizing at 9–11
months old (‘‘mid- stage pathology’’ cohort), and 2) 12–13 month
old mice were treated for 1 month and euthanized at 13–14
months of age (‘‘late-stage pathology’’ cohort). For both age
groups, LM11A-31 was dissolved in sterile water and administered
daily by oral gavage at 50 mg/kg/day. This dose was chosen
based on positive effects of the ligand on histological and
behavioral endpoints in previous studies from our laboratory
[14,16]. Furthermore, previous pharmacokinetic studies indicated
that LM11A-31 (50 mg/kg) delivered daily by oral gavage for 2
weeks resulted in brain concentrations of 1904 nM [14], which
greatly exceeds the in vitro effective dose [12]. Food was withheld
4 hours prior to dosing to aid in compound absorption. Vehicle-
treated mice received an equivalent volume per weight of sterile
water by the same route. Since LM11A-31 did not significantly
affect any measure analyzed in the 6–8 month old WT mice, this
group was not included in the study using 12–13 month old mice.
Starting at the first week of treatment, APPL/S mice weighed
significantly less than WTs at both of the age groups studied, as
neuropathology is present at the ages that treatment was started
[14,16,19] (Figure 1). The body weights of the APPL/S or WT
mice in the LM11A-31groups did not differ from those of their
respective genotypes given vehicle before or during treatment.
For treatment of Tg2576 mice, LM11A-31 was delivered via
drinking water. To determine dosing, LM11A-31 was adminis-
tered to C57BL/6 mice ad libitum in drinking water for 3 months
at targeted doses of 10, 50, 75 and 100 mg/kg/day (n = 3–4 mice/
dose). Brain concentrations of the ligand were determined by LC-
MS/MS at Absorption Systems (Exton, PA; for methods see [14]).
A targeted dose of 75 mg/kg/day produced a brain concentration
of 256666 nM. This concentration was higher than that resulting
from 10 and 50 mg/kg/day doses and the concentration (100 nM)
that provided neuroprotection in in vitro studies [13], but very
similar to that seen with 100 mg/kg/day (Figure 2). Therefore,
75 mg/kg/day was selected as the target dose for the Tg2576
study. Female Tg2576 mice and their non-transgenic (nTg)
littermates were allowed ad libitum access to drinking water
containing LM11A-31 (0.6 mg/ml; targeted dose 75 mg/kg) for 3
months starting at 14 months of age. Water bottles were refilled
every 3 days and were weighed before and after filling to estimate
doses received. Starting from treatment week 6, Tg2576 mice
weighed significantly less than nTg mice; LM11A-31 did not
significantly affect the body weights of either genotype (Fig-
ure 3A). Tg2576 mice consumed significantly more water than
nTg mice (Figure 3B) and because of their lower body weights
those in the treatment group received higher mean daily doses of
LM11A-31. Actual mean dose per treatment group in mg/kg/day
was: 79 for nTg and 119 for Tg2576 mice.
Immunohistochemistry
After treatment, all mice were deeply anesthetized with avertin
(2,2,2,tribromoehthanol; 425 mg/kg) and perfused with heparin-
ized saline. Brains were removed, post-fixed in 4% paraformal-
dehyde for 24 hours at 4uC, and then cryoprotected in 30%
sucrose. Brains were sectioned (40 mm, coronal) using a freezing
microtome. Free-floating sections (every 8th section in a 1 to 16th
series) were processed for immunohistochemical localization of
choline acetyltransferase (ChAT; 1:600; Millpore, Billerica, MA),
as a marker for BFCNs, or p75NTR using an antibody that
recognizes the extracellular domain of the receptor (1:800;
Neuromics, Edina, MN). Sections were incubated in the
Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA)
solution and visualized with a diamino-benzidine substrate kit
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(Vector). Amyloid plaques were labeled with 1% Thioflavin-S
(ThioS) stain.
Microscopy and quantitative analysis
All immunostaining was visualized with a Leica DM 5000B or a
Zeiss AxioImager M2 light microscope. Digitized images were
acquired with the latter microscope using AxioVision software
v4.7. Images for figures were acquired with a Zeiss AxioImager
M2 light microscope using a 10, 20 or 636 oil objective and
AxioVision software v4.7. All quantitative analyses were per-
formed by experimenters that were blind to the treatment and
genotype conditions.
In the basal forebrain, ChAT immunolabeling was viewed with
a 406 objective and, using methods adapted from previous work
[8,14,16], was evaluated in the vertical limb of the diagonal band
of Broca (VDB), which was defined as the area below the anterior
commissure (anterior part) at the rostro-caudal level of the islands
of Calleja and before the emergence of the horizontal diagonal
band (,Bregma 0.98 mm [23]). After this anatomical criteria was
applied only one section qualified for analysis when every 8th
section was processed. Brain sections were analyzed with
Neurolucida v8 image analysis software (MBF Bioscience) using
Figure 1. Body weight is not affected by treatment with
LM11A-31 in male APPL/S mice. Body weights of (A) 9–11 month old
male APPL/S mice treated with LM11A-31 (50 mg/kg) for 3 months (WT
Veh, n = 9 mice; WT-31, n = 10; APP Veh, n = 10; APP-31, n = 9) and (B)
13–14 month old male APPL/S mice treated with LM11A-31 (50 mg/kg)
for 1 month (WT Veh, n = 5 mice; APP Veh, n = 4; APP-31, n = 5). APP
mice weighed significantly less than WT mice in both of the age groups
examined. LM11A-31 did not affect body weight at either age or
genotype. Statistical significance was determined using repeated
measures ANOVA with Dunnett’s post-hoc test.
doi:10.1371/journal.pone.0102136.g001
Figure 2. Brain concentrations of LM11A-31 delivered ad
libitum in drinking water of C57BL/6 mice. LM11A-31 was given
to C57BL/6 mice ad libitum in drinking water for 3 weeks at targeted
doses of 10, 50, 75 and 100 mg/kg/day (n = 3–4 mice/dose). Brain
concentrations were determined by LC-MS/MS by Absorption Systems
(Exton, PA).
doi:10.1371/journal.pone.0102136.g002
Figure 3. Body weight and water consumption are not affected
by LM11A-31 treatment in Tg2576 mice. (A) Body weight of 17
month old female Tg2576 mice treated with LM11A-31 for 3 months
(nTg-Veh, n = 7 mice; Tg2576-Veh, n = 6; Tg2576-31, n = 5; nTg–LM11A-
31, n = 4). Starting at treatment week 6, Tg2576 mice weighed less than
WT mice; LM11A-31 had no effect on this measure. Statistical
significance was determined using repeated measures ANOVA with
Dunnett’s post-hoc test. (B ) Average grams of water consumed by
Tg2576 mice over 3 days was significantly greater than nTg mice;
LM11A-31 had no effect on this measure. Statistical significance was
determined using two-tailed Student’s t-test. *p#0.05 vs. nTg Veh.
doi:10.1371/journal.pone.0102136.g003
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an unbiased automated scanning procedure (Meander Scan) that
allows fields within a user-defined contour to be seen without
overlap. In every third field, all neurons, and processes originating
from them, were manually traced while focusing in the z-plane
throughout the section to accurately assess volume and branching
and to clearly discern the origin and end of neurites emanating
from a particular cell. The software program moves the field of
view to track the neurite throughout the VDB and realigns the
tracing ensuring that the neurite is traced in its entirety in the x-
and y-planes. Neurolucida Branched Structure Analysis was used
to compute the volume, length, surface area, and branching order
of the neurites.
Using methods previously established in our laboratory [14],
ChAT immunostaining and ThioS staining in the motor and
primary somatosensory cortices (between ,Bregma 1.18–0.74
[23]) was visualized with a 106objective and one digitized image
was taken from each side of the brain in 3 sections per animal for a
total of 6 fields/animal (sample field = 9006670 mm2). The same
sample fields were analyzed for both stains. Clusters of ChAT-
stained dystrophic neurites were manually traced by outlining their
perimeter using Neurolucida v8 and the Branched Structure
Analysis function was used to compute the area. ThioS staining
was quantified from the digital images using histogram threshold-
ing in Image Pro Plus v6.3 software (Media Cybernetics). The
threshold was set manually to identify dense immunolabeling that
was distinct from the background. The immunostained area was
expressed as a percentage of the total area analyzed.
p75NTR-immunolabeling was visualized with a 206objective in
2 sections per mouse in the basal forebrain (both medial septum
and VDB), defined as the area above and below the anterior
commissure (anterior part) at the rostro-caudal level of the islands
of Calleja and before and just after the emergence of the
horizontal diagonal band (,Bregma 0.98–0.86 mm [23]). Three
to four non-overlapping images were taken per section each using
a 4506335 mm2 sample field. p75NTR-immunostained soma and
neurites were automatically thresholded after background sub-
traction using ImageJ. The immunostaining area and density of
both soma and neurites was measured and the number of soma
was manually counted.
Statistical analyses
GraphPad Prism v5 (GraphPad Software, San Diego California)
was used to determine significance using a one-way Analysis of
Variance (ANOVA) with Dunnett’s multiple comparison post-hoc
test and, when appropriate, a two-tailed Student’s t-test. For
planned comparisons in which a direction of difference was
predicted, a one-tailed Student’s t-test was used. A 262
contingency table with a Fisher’s Exact test was used to determine
the statistical significance of analyses with categorical variables
(e.g. presence or absence of dendrite branching). For body weights,
a repeated measures ANOVA with Dunnett’s post-hoc test was
used. Results are expressed as group mean 6 SEM and statistical
significance was set at p#0.05.
Figure 4. LM11A-31 normalizes increased p75NTR levels in the basal forebrain of late-stage APPL/S mice. Representative
photomicrographs show p75NTR immunostaining in the vertical limb of the diagonal band of the basal forebrain in (A) WT Vehicle (Veh), (B )
APPL/S (APP) Veh, and (C ) APP LM11A-31 (-31) mice at 13–14 months old. Scale bar = 40 mm. Quantitative analysis showed that, at this age, the (D )
area occupied by (**p#0.01) and (E) the density (*p,0.05) of p75NTR immunostaining is increased in APP Veh compared to WT Veh mice, while the
increase in the number of p75NTR-stained cells was not statistically significant. LM11A-31 normalized p75NTR levels (+p#0.05 vs. APP Veh for both area
and density). Statistical significance was determined using a one-way ANOVA with Dunnett’s post-hoc test (WT Veh, n = 5 mice; APP Veh, n = 4; APP-
31, n = 5).
doi:10.1371/journal.pone.0102136.g004
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Figure 5. LM11A-31 prevents and/or reverses basal forebrain cholinergic neurite atrophy in mid-stage APPL/S mice. Representative
photomicrographs show ChAT-immunostained neurons in VDB of the basal forebrain of (A) WT Veh, (B ) WT LM11A-31 (-31), (C ) APPL/S (APP) Veh,
and (D ) APP-31 mice at 9–11 months of age. Arrowheads indicate the distal part of neurites. Below each photomicrograph are reconstructed
drawings from Neurolucida tracings of two ChAT-stained neurons per treatment group. The left drawing is the neurite and corresponding soma
indicated by the arrowhead in the photomicrograph (orientations were altered). The right drawing is of a cell outside the field displayed in the
photomicrograph but within the field analyzed. Scale bar in A = 20 mm and also applies to the line drawings. Quantification indicates that treating
APPL/S mice with LM11A-31 for 3 months increases the (E ) length, (F ) area occupied by, and (G ) branching of BFCN neurites compared to those given
vehicle. Statistical significance was determined using an ANOVA with Dunnett’s post-hoc test and, for branching, a 262 contingency table with
Fisher’s exact test (WT Veh, n = 9 mice; WT-31, n = 10; APP Veh, n = 10; APP-31, n = 9). **p#0.01 and ***p,0.001 vs. WT Veh; +p#0.05 and ++p#0.01 vs.
APP Veh.
doi:10.1371/journal.pone.0102136.g005
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Results
Effects of LM11A-31 on p75NTR levels in basal forebrain of
APPL/S mice
Since levels of p75NTR have been shown to increase in AD
patients [24,25] and mouse models [26,27] with late-stage
pathology and p75NTR is the target of LM11A-31, we determined
whether p75NTR immunostaining was increased in the basal
forebrain of APPL/S mice at the ages involved in this study, and if
levels were affected by the ligand, which could suggest target
engagement. P75NTR immunostaining did not differ between 9–11
month old APPL/S and WT mice given vehicle and LM11A-31
treatment had no effect on this measure (data not shown). In
contrast, in late-stage APPL/S mice (13–14 months of age), the area
occupied by p75NTR staining associated with neurons and neurites
was significantly increased by 3768.5% and density was elevated
by 3165.2%, compared to WT mice (Fig. 4A–E). The number of
p75NTR-stained cells increased slightly but this difference was not
statistically significant (Fig. 4F). The increased area of p75NTR
immunostaining is most likely due to increased p75NTR levels in
neurons/neurites since the staining density significantly increased
but the number of p75NTR-stained cells did not. Furthermore,
previous reports showed that BFCN number, as assessed with
ChAT immunostaining, was unaltered in APPL/S mice compared
to WTs [8,14]. LM11A-31 treatment inhibited the increases in
p75NTR immunostaining in the basal forebrain of APPL/S mice.
This finding is consistent with our prior in vitro studies
demonstrating that LM11A-31, like NGF, induces p75NTR
endocytosis and proteolytic processing and that the latter also
occurs after administration to APPL/S mice [16]. Thus, p75NTR is
present in abundance on the cells of interest in this study, showing
feasibility of the ligand acting through its intended target, and
LM11A-31 treatment decreases p75NTR levels, which is consistent
with target engagement.
LM11A-31 prevents progression of and/or reverses
cholinergic neuritic dystrophy in mid-stage APPL/S mice
Since we previously found that treating 3–5 month old male and
female APPL/S mice with LM11A-31 for 3 months slowed the
progression of cholinergic neurite dystrophy [14,16], we sought to
determine if LM11A-31 could prevent the progression of, and/or
reverse, cholinergic neurite dystrophy with treatment beginning at
a mid-pathological stage of the disease (6–8 months old). APPL/S
mice develop dense amyloid deposits in the frontal cortex and
hippocampus at 3–4 and 5–7 months of age, respectively [19], and
amyloid deposition progressively increases thereafter. BFCN loss
does not occur in APPL/S mice at 6–8 months, but atrophy of
cholinergic neurites is evident [1,8,14,16]. For example, the length
of BFCN neurites in APPL/S mice is ,30% shorter than those in
WT mice at that age [14,16]. Moreover, hippocampal projection
fibers of BFCNs are modulated by p75NTR in WT mice [28] as are
ChAT-containing neurites in APPL/S mice [8]. Finally, mild
Figure 6. LM11A-31’s effect on cholinergic dystrophic neurites in cortex of mid-stage APPL/S mice. Representative photomicrographs
show ChAT-immunostained dystrophic neurite clusters in the cortex of (A) APPL/S (APP) Veh and (B ) APP-31 mice. Scale bar in photomicrograph
A = 50 mm. Quantitative analysis showed that LM11A-31 decreases the total area occupied by the clusters (C ) by decreasing their number (D ) but not
the mean area per cluster (E ). Statistical significance was determined using a two-tailed Student’s t-test (APP Veh, n = 10; APP-31, n = 9). +p = 0.03 and
+++p = 0.001 vs. APP Veh.
doi:10.1371/journal.pone.0102136.g006
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cognitive deficits are first seen in APPL/S mice at 3 months [21],
are significantly worse at 6–8 months, and then progressively
increase [14,16,20,21].
We examined the effects of LM11A-31 on the length and
surface area of ChAT- immunolabeled neurites in the VDB
because it provides a larger cholinergic projection to the cortex
and hippocampus than the medial septum [29,30]. The mean
number of neurons analyzed per mouse was 7163. The length of
ChAT containing neurites of BFCNs appeared shorter in vehicle-
treated mid-stage APPL/S mice (9–11 months old) than any of the
other groups (Fig. 5A–D). Quantitative analyses showed that
ChAT-stained neurites were 3965% shorter in vehicle-treated
APPL/S mice relative to their WT littermates (Fig. 5E) and their
surface area was decreased by 4166% (Fig. 5F). All mice of both
genotypes had ChAT-positive neurites with 2nd order branching,
however, significantly fewer APPL/S mice had neurites with $3rd
order branching compared to WT mice (Fig. 5G).
Treating mid-stage APPL/S mice with LM11A-31 eliminated
neurite degeneration as the length and surface area of their ChAT-
stained neurites was equal to that of vehicle-treated WT mice
(Fig. 5B, C). Furthermore, the reduction in branching complexity
seen in vehicle-treated APPL/S mice was markedly reduced with
LM11A-31, as 6 of 9 treated APPL/S mice had ChAT neurites
with $3rd order branching compared to 1 of 10 in the vehicle
group (Fig. 2G). LM11A-31 did not affect the length, surface area
or branching of BFCN neurites in WT mice (Fig. 5D, E–F).
Since basal forebrain neurons are the main source of cholinergic
innervation to the cortex [30] and cholinergic fibers become
increasingly dystrophic with age in the vicinity of cortical amyloid
plaques [14,31,32,33], we examined the effects of LM11A-31
treatment on cholinergic dystrophic neurites in this region. Large
clusters of dystrophic ChAT-stained neurites were prominent in
the cortex of vehicle-treated APPL/S mice (Fig. 6A), but were
absent in WT mice (not shown). LM11A-31 decreased the total
area occupied by ChAT-immunostained clusters in APPL/S mice
(Fig. 6B,C) by reducing the number of ChAT clusters (Fig. 6D)
not the area per cluster (Fig. 6E).
LM11A-31 did not affect the percentage of the area occupied by
ThioS staining in the cortex of APPL/S mice (0.3860.07% for
vehicle group vs. 0.4360.08% for LM11A-31). These results
corroborate our previous studies indicating that fibrillar forms of
Ab were not affected by the ligand in APPL/S mice at earlier
Figure 7. LM11A-31 prevents atrophy of cholinergic neurites in basal forebrain of late-stage APPL/S mice. Representative
photomicrographs show ChAT-immunostained neurons in the basal forebrain of (A) WT Veh, (B ) APPL/S (APP) Veh, and (C ) APP-31 mice at 13–14
months of age. Arrowheads indicate the distal part of neurites. Scale bar in A = 40 mm. Below each photomicrograph are reconstructed drawings from
Neurolucida tracings of two ChAT-stained neurons per treatment group indicated by the arrowhead in the photomicrograph. Scale bar in drawing
under A = 40 mm. Quantitative analysis showed that treating late-stage APPL/S mice with LM11A-31 for 1 month prevented the decreases in (D )
length, (E ) surface area, and (F ) branching of cholinergic neurites in basal forebrain, although the latter measure did not reach statistical significance.
Statistical significance was determined using an ANOVA with Dunnett’s post-hoc test and/or two-tailed Student’s t-test for BFCN neurite
degeneration and, for branching, a 262 contingency table with Fisher’s exact test (WT Veh, n = 5 mice; APP Veh, n = 4; APP-31, n = 5). *p,0.05, **p#
0.01 and ***p,0.001 vs. WT Veh; +p,0.05 and ++p#0.01 vs. APP Veh.
doi:10.1371/journal.pone.0102136.g007
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disease stages [14,16]. In addition, we previously reported that
soluble Ab(1-42) levels were not affected by the same LM11A-31
treatment [14]. Therefore, decreases in Ab levels are unlikely to
contribute to LM11A-31’s prevention and/or reversal of ChAT
neurite dystrophy.
LM11A-31 reverses cholinergic neuritic dystrophy in
late-stage APPL/S mice
Given the prominent cholinergic neurite degeneration already
present in APPL/S mice at 6–8 months of age [14,16] when
treatment in the present study was initiated, the above findings
that LM11A-31 treatment largely normalized cholinergic neurites
suggested that the ligand, to a significant extent, reversed rather
than simply slowed cholinergic neurite dystrophy. In order to
further evaluate the existence of a reversal effect, we determined
whether similar results could be obtained with a shorter (1 month)
LM11A-31 treatment beginning in late-stage APPL/S mice (12–13
months old) with more advanced pathology.
Within the 13–14 month old group, vehicle-treated APPL/S
mice had ChAT-stained neurites in the basal forebrain that were
5865% shorter and occupied 6064% less area than those of WT
mice (Fig. 7A–E). Furthermore, all of the vehicle-treated WT
mice at this age had neurites with $3rd order branching, while
only 1 of 4 APPL/S mice had this characteristic (Fig. 7F). LM11A-
31 prevented deficits in both neurite length and area in 13–14
month old APPL/S mice compared to those given vehicle
(Fig. 7D,E). It also increased the number of APPL/S mice that
had neurites with $3rd order branching (3 out of 5 mice), however
this increase did not reach statistical significance (Fig. 7F). In the
cortex, LM11A-31 did not affect the total area occupied by or the
number of ChAT neurite clusters but did significantly decrease the
area per cluster (Fig. 8A–E). As in 9–11 month old APPL/S mice,
LM11A-31 did not affect the area of ThioS staining in the cortex
of the late-stage APPL/S mice (0.6060.14% for vehicle group vs.
0.5160.08% for LM11A-31). These results suggest that LM11A-
31 may slow cluster expansion and coalescence and/or promote
their disintegration.
Aging significantly affected ChAT neurites in APPL/S mice but
not in WT mice. Vehicle-treated WT mice at 13–14 months of age
had ChAT neurites in the basal forebrain that were nearly
identical in length and the area they occupied compared to those
in 9–11 month old mice. In contrast, as predicted for a progressive
degenerative disease, 13–14 month old APPL/S mice had ChAT
neurites with reduced length and area compared to those in 9–11
month old APPL/S mice (Fig. 9A,B). Moreover, the total area and
size of ChAT-stained dystrophic neurite clusters in the cortex were
Figure 8. LM11A-31 prevents cholinergic dystrophic neurites in cortex of late-stage APPL/S mice. Representative photomicrographs
show clusters of cholinergic dystrophic neurites in the cortex of APPL/S (APP) Veh (A) and APP-31 (B ) mice. Scale bar in B = 50 mm. Quantitative
analysis showed that LM11A-31 did not significantly affect the total area (C ) or number (D ) of clusters but did decrease the size or mean area per
cluster (E ). Statistical significance was determined using a two-tailed Student’s t-test. ++p#0.01 vs. APP Veh.
doi:10.1371/journal.pone.0102136.g008
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increased substantially in the 13–14 versus 9–11 month old APPL/
S mice (Fig. 9C,D). However, the number of cortical dystrophic
neurite clusters and ChAT neurite branching did not significantly
change between these age groups (compare Figs. 6 and 8, 5 and
7).
Notably, the 13–14 month old APPL/S mice treated with
LM11A-31 had ChAT neurites with significantly greater length,
area (Fig. 9A,B), and branching (p = 0.02, one-tailed Chi-square)
than 9–11 month old vehicle-treated APPL/S mice. This finding
suggests a reversal of pathology rather than a mere slowing of
progression. The reduced area of cortical ChAT neurite clusters
seen in the 13–14 month old APPL/S mice given LM11A-31 does
not necessarily include a reversal effect as the total area and area
per cluster were still significantly higher than in the 9–11 month
old vehicle-treated APPL/S mice (Fig. 9C,D).
Cholinergic neuritic dystrophy is ameliorated with
LM11A-31 treatment in mid- to late-stage Tg2576 mice
To further assess the robustness of the effect of LM11A-31 in
slowing progression of degeneration, we determined whether the
ligand would be effective in reducing neurite degeneration in
another well-characterized AD mouse model, Tg2576 mice.
LM11A-31 was administered to female Tg2576 mice and their
nTg littermates for 3 months starting at 14 months of age. In these
mice, cognitive deficits are seen at 3 months of age and are
progressive [34,35,36]. Insoluble Ab levels incrementally increase
beginning at 6 months of age [37] and Ab deposition is evident at
11 months [22,38]. Cholinergic dystrophic neurites are not seen at
8 months of age but occur in the cortex by 16 months [39].
In comparison to nTg mice, vehicle-treated Tg2576 mice at 17
months old had shorter ChAT-stained neurites in the basal
forebrain that occupied less area (Fig. 10A,B). These deficits were
prevented in Tg2576 mice given LM11A-31, which had cholin-
ergic neurites resembling those of nTg mice. Dendrite branching
complexity was also decreased in vehicle-treated Tg2576 mice but
not in those given LM11A-31, compared to nTg mice (Fig. 10C).
Finally, LM11A-31 did not affect the number of cholinergic
dystrophic neurite clusters in the cortex, but significantly reduced
the total area they occupied as well as the mean area per cluster
(Fig. 10D–F). LM11A-31 did not affect any measure in nTg
mice. These findings confirmed the ability of LM11A-31
treatment to prevent neurite degeneration in a second mouse
model. The extent to which treatment might reverse degeneration
in this model will require studies at later disease stages.
Discussion
This study showed that administering the p75NTR ligand
LM11A-31 to APPL/S mice with mid- to late-stage pathology
slowed the progression of cholinergic neurite degeneration in the
basal forebrain and cortex and this effect was confirmed in the
Tg2576 model. Importantly, LM11A-31 reversed degeneration
when it was administered for a brief duration (1 month) and
initiated at an age (12–13 months) that was about four times older
than the age of detectable pathology onset (3–4 months old). To
our knowledge, this report is the first to demonstrate that a CNS
penetrating small molecule can function at a specific target to
reduce and/or reverse fundamental AD pathologies in late-stage
AD mice.
The length and branching complexity of ChAT-stained
dendrites in the basal forebrain was reduced in mid- and late-
stage APPL/S mice as well as Tg2576 mice. LM11A-31 reversed
these changes. Dendritic abnormalities and decreases in higher
order branching have also been observed in the hippocampus,
basal forebrain, and/or cortex of Tg2576 mice [40] and in other
AD mouse models and patients [32,41,42,43,44]. Shorter and less
branched dendrites are correlated with dementia [41,45], most
likely due to decreased neuronal connectivity, and may therefore
contribute to the memory deficits described in APPL/S and
Tg2576 mice. LM11A-31 may have exerted its effects on dendritic
length and complexity via activation of the PI3K/AKT pathway
as the ligand increases AKT signaling [12] and this pathway has
been shown to increase dendrite branching and alter dendritic
arbor shape [46].
Dystrophy of cholinergic neurites in the basal forebrain and
cortex is exacerbated in an age-dependent manner in APPL/S
mice. These results are consistent with those seen in other mouse
Figure 9. LM11A-31 reverses dystrophy of cholinergic neurites
that occurs with aging in APPL/S mice. Quantitative analysis of the
effect of aging showed that 13–14 month old vehicle-treated APPL/S
(APP) mice had ChAT neurites in basal forebrain with decreased (A)
length and (B ) area and had dystrophic neurite clusters in cortex that
occupied more area (C ) and were larger (D ) compared to the 9–11
month old APP Veh mice. In 13–14 month old APP mice, LM11A-31
increased the length and area of ChAT neurites in basal forebrain while
decreasing the area of cortical dystrophic neurites compared to vehicle-
treated mice (A–D ; absolute numbers shown in Figs. 4 and 5). The
effect of LM11A-31 in the basal forebrain was a reversal as neurite
length (A) and area (B ) were significantly greater in 13–14 month old
APP-31 mice than 9–11 month old APP Veh mice. In the cortex, LM11A-
31 did not reverse the area occupied by dystrophic neurites as 13–14
month old APP-31 mice still had significantly larger clusters than 9–11
month old APP Veh mice (C, D ). Results are expressed as a percentage
of the 9–11 month old APP Veh group. Statistical significance was
determined using one-tailed Student’s t-test (For 9–11 month old APP
Veh n = 10; For 13–14 month group: APP Veh, n = 4; APP-31, n = 5). *p#
0.05, **p#0.005 and ***p#0.001 vs. 9–11 month old APP Veh; +p#0.05
and ++p#0.01 vs. 13–14 month old APP Veh.
doi:10.1371/journal.pone.0102136.g009
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models of AD [31,32,33]. Notably, LM11A-31 reversed the effect
aging has on cholinergic neurite dystrophy and eliminated the age-
related increase in p75NTR levels in the basal forebrain of APPL/S
mice. This latter effect could be due to LM11A-31-induced
receptor internalization and/or processing or it could be
secondary to decreasing pathology, as numerous mechanisms of
cellular injury, including those related to AD, up-regulate p75NTR
[3,25,47,48]. The LM11A-31-induced decrease in p75NTR levels
may account, in part, for the reversal of cholinergic deficits by
decreasing the abnormally high p75NTR/Trk ratio in the basal
forebrain found in human AD and mouse models [25,26,47,48].
The reversal effects in aged APPL/S mice occur even when
treatment is shortened to 1 month and initiated after appreciable
pathology has developed. This reversal holds particular relevance
to translating a small molecule p75NTR ligand to the clinic,
wherein AD patients, even at early clinical stages, would more
likely be in pathologically advanced stages of disease prior to
treatment.
LM11A-31-treated APPL/S mice with mid-stage pathology had
fewer dystrophic neurite clusters in the cortex that occupied a
smaller area but did not decrease in size. Although a reversal effect
did not occur in the cortex of late-stage APPL/S mice, just 1 month
of LM11A-31 treatment reduced cluster size without affecting
their number or overall area. Perhaps a longer treatment time
would have reversed the total area and size of the clusters to the
levels of the 9–11 month old vehicle-treated APPL/S mice.
Nevertheless, reducing either the size or the number of dystrophic
neurite clusters could be beneficial and an indicator of slowing
degenerative processes.
The positive results achieved here with LM11A-31 further
validate p75NTR as a therapeutic target for AD. The ability to
reverse neurite degeneration in the context of ongoing, late-stage
Ab accumulation is particularly notable in terms of the array of
fundamental AD-related signaling mechanisms modulated by
LM11A-31. p75NTR and TrkA signaling stimulated by NGF
binding are essential for BFCN function and survival, and this
signaling is disrupted in AD brains [49,50,51]. Furthermore,
degenerative signaling is augmented in AD due, in part, to
increased p75NTR/Trk ratios [52,53,54], elevated proNGF levels
[15,55,56,57], and Ab interactions either directly and/or indi-
rectly with p75NTR [58]. LM11A-31 competes with NGF and
proNGF binding to p75NTR but not TrkA [12,15] and has a
signaling profile that is distinct from NGF [12]. Our previous in
vitro studies showed that LM11A-31 inhibited Ab-induced
degenerative signaling (including excess activation of GSK3b,
cdk5 and JNK), activated survival signaling that is compromised in
AD (AKT and NFkB), and prevented excess tau phosphorylation
in a p75NTR-dependent manner [13]. These actions and the
present in vivo results showing prevention and reversal of BFCN
degeneration are consistent with the idea that LM11A-31 can bind
to p75NTR to simultaneously increase survival signaling while
decreasing degenerative signaling to ameliorate mid- to late-stage
AD-related pathology.
Figure 10. LM11A-31 prevents dystrophy of cholinergic neurites in mid- to late-stage female Tg2576 mice. Quantitative analysis
showed that treating female Tg2576 mice starting at 14 months of age with LM11A-31 for 3 months prevented and/or reversed the decreases in (A)
length, (B ) surface area, and (C ) branching of BFCN neurites. This treatment also decreased the total area (D ) occupied by the clusters of cholinergic
dystrophic neurites in the cortex and the mean area per cluster (F ) but did not affect the number (E ). Statistical significance was determined using an
ANOVA with Dunnett’s post-hoc test for BFCN neurite degeneration, a 262 contingency table with a Fisher’s exact test for branching, and a two-
tailed Student’s t-test for clusters (nTg-Veh, n = 7 mice; Tg2576-Veh, n = 6; Tg2576-31, n = 5; nTg–LM11A-31, n = 4). *p#0.05 vs. nTg veh; +p#0.05 vs.
Tg2576-Veh.
doi:10.1371/journal.pone.0102136.g010
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In all, these results suggest that targeting of p75NTR is a
promising approach to modulating AD-related degenerative
mechanisms in a way that is sufficiently robust to affect
pathological processes that have progressed beyond early stages.
Future studies will include behavioral analyses to assess whether
reversing these neuropathologies improves functional outcomes.
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